Molecular detection of OXA-48 and NDM-1 carbapenemase genes among clinical isolates of Klebsiella pneumoniae recovered from patients attending a private tertiary hospital in Southwestern Nigeria

被引：0

作者：

Chisom Blossom Onyeji ^{[1
]}

Seyi Samson Enitan ^{[1
]}

Olalekan Ademola Kemiki ^{[2
]}

Abigail Chinyere Igwe ^{[2
]}

Akinbobola Ayokunle Adeniyi ^{[3
]}

Michael Unata Iduh ^{[4
]}

Grace Eleojo Itodo ^{[5
]}

Ayomide Oluwatobiloba Okuneye ^{[1
]}

Precious Oluwatosin Adamson ^{[1
]}

Mofeoluwa Favour Kolawole ^{[1
]}

机构：

[1] Department of Medical Laboratory Science, School of Public and Allied Health, Babcock University, Ogun State, Ilishan-Remo

[2] Molecular and Tissue Culture Laboratory, Babcock University Teaching Hospital, Ogun State, Ilishan-Remo

[3] Department of Medical Microbiology, University College Hospital, Oyo State, Ibadan

[4] Department of Medical Microbiology, School of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto State, Sokoto

[5] Department of Microbiology, Federal Teaching Hospital, Kogi State, Lokoja

来源：

BMC Infectious Diseases | / 24卷 / 1期

关键词：

Carbapenemase genes; Klebsiella pneumoniae; NDM-1; OXA-48; Southwestern nigeria;

D O I：

10.1186/s12879-024-09869-x

中图分类号：

学科分类号：

摘要：

Abstract: There have been increasing reports of Klebsiella pneumoniae resistant to β-lactam antibiotics. This study aimed to determine the prevalence of some selected carbapenemase genes among clinical isolates of Klebsiella pneumoniae recovered from patients attending a private tertiary hospital in Southwestern Nigeria. The study was conducted over two months (February-March 2024). A total of 50 clinical isolates of Klebsiella pneumoniae from different clinical specimens were obtained from the Medical Microbiology Department, Babcock University Teaching Hospital (BUTH). The clinical isolates were then characterized using standard microbiological procedures and were tested for susceptibility to meropenem and other classes of antibiotics according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Polymerase Chain Reaction (PCR) detection for OXA-48 and NDM-1 carbapenemase genes was performed on the 50 clinical isolates. PCR analysis showed that 9 (18%) clinical isolates were positive for the OXA-48 gene, 22 (44%) were positive for the NDM-1 gene, 4 (8%) possessed both the OXA-48 and NDM-1 genes, and 23 (46%) possessed neither the OXA-48 nor NDM-1 genes. Antibiotic Susceptibility Testing (AST) revealed that all the clinical isolates were resistant to meropenem. In conclusion, this study demonstrates the presence of OXA-48 and NDM-1 genes in clinical isolates of Klebsiella pneumoniae recovered from patients attending a private tertiary hospital in Southwestern Nigeria, highlighting the role of ESBL (extended-spectrum beta-lactamase) as a major resistance mechanism alongside other mechanisms. Population-based surveillance programs should be implemented to monitor the prevalence and epidemiology of Klebsiella pneumoniae infections at the community level, facilitating early detection of outbreaks and identification of emerging antimicrobial resistance patterns. Core Tip: This study highlights the significant prevalence of NDM-1 and OXA-48 carbapenemase genes among Klebsiella pneumoniae clinical isolates in a private tertiary hospital in Southwestern Nigeria, with 44% and 18% of isolates harboring these genes, respectively. Notably, 46% of isolates were resistant to carbapenems despite lacking these genes, suggesting alternative resistance mechanisms. The findings underscore the urgent need for enhanced surveillance, infection control measures, and antibiotic stewardship programs to combat the spread of multidrug-resistant Klebsiella pneumoniae in healthcare settings. © The Author(s) 2024.

引用

共 70 条

[1] Yu W., Luo Q., Shen P., Chen Y., Xu H., Xiao Y., &Qiu Y., New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae, Int J Antimicrob Agents, 58, 6, (2021)
[2] Alhazmi W., Al-Jabri A., Al-Zahrani I., The Molecular Characterization of Nosocomial Carbapenem-Resistant Klebsiella pneumoniae Co-Harboring bla NDM and bla OXA-48 in Jeddah, Microbiology Research, 13, 4, pp. 753-764, (2022)
[3] Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L., Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An evolving crisis of global dimensions, Clinmicrobiol Rev, 25, 4, pp. 682-707, (2012)
[4] Nordmann P., Carbapenemase-producing Enterobacteriaceae: Overview of a major public health challenge, Medicine and Infectious Diseases, 44, 2, pp. 51-56, (2014)
[5] Sharma R., Garcia E., Diep J.K., Lee V.H., Minhaj F., Jermain B., Ellis-Grosse E.J., Abboud C.S., Rao G.G., Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae, Int J Antimicrob Agents, 59, 4, (2022)
[6] Wang N., Zhan M., Liu J., Wang Y., Hou Y., Li C., Et al., Prevalence of carbapenem-resistant Klebsiella pneumoniae infection in a Northern province in China: Clinical characteristics, drug resistance and geographical distribution, Infect Drug Resist, 15, pp. 569-579, (2022)
[7] Hu Y., Liu C., Shen Z., Zhou H., Cao J., Chen S., Et al., Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018, Emerging Microbes and Infections, 9, 1, pp. 1771-1779, (2020)
[8] Mouktaroudi M., Kotsaki A., Giamarellos-Bourboulis E.J., Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae, Expert Rev Anti-Infective Therapy, 20, 6, pp. 809-818, (2022)
[9] Fuster B., Tormo N., Salvador C., Gimeno C., Detection of two simultaneous outbreaks of Klebsiella pneumoniae coproducing OXA-48 and NDM-1 carbapenemases in a tertiary-care hospital in Valencia, Spain, New Microbes and New Infections, 34, (2020)
[10] Paul M., Carrara E., Retamar P., Tangden T., Bitterman R., Bonomo R.A., de Waele J., Daikos G.L., Akova M., Harbarth S., Pulcini C., Garnacho-Montero J., Seme K., Tumbarello M., Lindemann P.C., Gandra S., Yu Y., Bassetti M., Moutin J.W., Tacconelli E., Rodriguez-Bano J., European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli, Clin Microbiol Infect, 28, 4, pp. 521-547, (2022)

← 1 2 3 4 5 6 7 →